NIH-funded study shows sorafenib improves progression-free survival for patients with rare sarcomas

Interim results from a clinical trial for patients with desmoid tumors or aggressive fibromatosis (DT/DF) show that the drug sorafenib tosylate (Nexavar) extended progression-free survival compared with a placebo.

https://ift.tt/2pLkPTp